Latest Breaking News On - Nd me us90138q1085 - Page 1 : comparemela.com

First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral. | April 14, 2023

United statesHead of therapeutics developmentAmerican association for cancer researchEastern cooperative oncology groupMe holding coAmerican associationCancer researchAnnual meetingJennifer lowTherapeutics development23andme holding co stock exchangePress releaseNd me us90138q1085